A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer

Inclusion Criteria: * Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors or non-Hodgkin's lymphomas for which YM155 has the potential, based on preclinical and/or clinical data, to show efficacy, namely: * castrate resistant prostate cancer * non-small cell lung cancer * metastatic melanoma * muscle invasive bladder cancer * follicular lymphoma * diffuse large B-cell lymphoma * Life expectancy ≥ 3 months; and Performance status (PS) ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale at baseline Exclusion Criteria: * Radiotherapy, major surgery, hormonal therapy, and chemotherapy within 4 weeks prior to the first dose of study medication and 6 weeks in the case of mitomycin-C or nitrosourea * Previous therapy with YM155 * Patients with renal, hepatic or colorectal cancers * Inadequate bone marrow, renal and/or hepatic function * History of being treated for other malignancy within 5 years except for treated basal or squamous cell carcinoma of the skin * Participation in any clinical study within 4 weeks prior to start of the first dose of study medication * Known brain or leptomeningeal metastases * Active uncontrolled systemic infection at baseline